PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of procrsmedFormerly medchtJournal of the Royal Society of MedicineProceedings of the Royal Society of Medicine
 
Proc R Soc Med. 1964 June; 57(6): 511–514.
PMCID: PMC1898067

Enzymes and Drug Sensitivity

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (611K), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • FREIRE-MAIA N, FREIRE-MAIA A, QUELCE-SALGADO A. Parity effect on abortions. Lancet. 1963 Apr 6;1(7284):774–775. [PubMed]
  • COWGER ML, LABBE RF, MACKLER B. Relation of barbiturate structure to DPNH oxidase inhibition. Arch Biochem Biophys. 1962 Mar;96:583–587. [PubMed]
  • DEAN G, BARNES HD. Porphyria in Sweden and South Africa. S Afr Med J. 1959 Mar 21;33(12):246–253. [PubMed]
  • DE MATTEIS F, RIMINGTON C. The biochemical disturbance in acute intermittent and experimental porphyria. Lancet. 1962 Jun 23;1(7243):1332–1334. [PubMed]
  • DE MATTEIS F, SLATER TF, WANG DY. Liver nucleotides in experimental hepatic porphyria. Biochim Biophys Acta. 1963 Jan 29;68:100–107. [PubMed]
  • GAJDOS A, GAJDOS-TOROK M. The therapeutic effect of adenosine-5-monophosphoric acid in porphyria. Lancet. 1961 Jul 22;2(7195):175–177. [PubMed]
  • GOLDBERG A. The effect of certain barbiturates on the porphyrin metabolism of rabbits. Biochem J. 1954 May;57(1):55–61. [PubMed]
  • GOLDBERG A, RIMINGTON C. Experimentally produced porphyria in animals. Proc R Soc Lond B Biol Sci. 1955 Jan 27;143(911):257–279. [PubMed]
  • LABBE RF, TALMAN EL, ALDRICH RA. Porphyrin metabolism. II. Uric acid excretion in experimental porphyria. Biochim Biophys Acta. 1954 Dec;15(4):590–591. [PubMed]
  • LONDON ID. Porphyria cutanea tarda; report of case successfully treated with chloroquine. AMA Arch Derm. 1957 Jun;75(6):801–803. [PubMed]
  • RIMINGTON C. Types of porphyria: some thoughts about biochemical mechanisms involved. Ann N Y Acad Sci. 1963 Mar 5;104:666–675. [PubMed]
  • DE MATTEIS F, RIMINGTON C. Disturbance of porphyrin metabolism caused by griseofulvin in mice. Br J Dermatol. 1963 Mar;75:91–104. [PubMed]
  • RIMINGTON C, MORGAN PN, NICHOLLS K, EVERALL JD, DAVIES RR. GRISEOFULVIN ADMINISTRATION AND PORPHYRIN METABOLISM. A SURVEY. Lancet. 1963 Aug 17;2(7303):318–322. [PubMed]
  • SCHMID R, SCHWARTZ S. Experimental porphyria. III. Hepatic type produced by sedormid. Proc Soc Exp Biol Med. 1952 Dec;81(3):685–689. [PubMed]
  • TEODORESCU S, BADANIOU A, GHEORGHIU G. Uber einen eigenartigen Zwischenfall im Verlaufe der Behandlung der kutanen Porphyrie des Erwachsenen mit synthetischen weissen Antipaludika. Dermatol Wochenschr. 1959 Apr 25;139(17):445–450. [PubMed]
  • WATSON CJ, RUNGE W, BOSSENMAIER I. Increased urinary porphobilinogen and uroporphyrin after administration of stilboestrol in a case of latent porphyria. Metabolism. 1962 Nov;11:1129–1133. [PubMed]

Articles from Proceedings of the Royal Society of Medicine are provided here courtesy of Royal Society of Medicine Press